Bulletins
Browse by topic
- View All
- Agricultural and Vet Science
- Arts, Culture and Performance
- Biology
- Built Environment and Design
- Business and Management
- Chemistry
- COVID-19 Related
- Digital Technology Supercluster
- Earth Sciences
- Economics
- Education
- Engineering
- Environmental Sciences
- History and Archaeology
- Human Society
- Indigenous Studies
- Information and Computing Science
- International Development
- Language, Communications and Culture
- Law and Legal Studies
- Mathematics
- Medical and Health Science
- Philosophy and Religious Studies
- Physics
- Policy and Political Science
- Psychology
- Research Tools
- Technology
Emergency Awards: PAR-20-177 Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).
Potential applicants are strongly encouraged to contact Scientific/Research staff before submitting an application to this FOA to determine whether or not the proposed work is within the intended scope of this program, whether requested expedite funding is likely to be available, and whether the idea should be considered for initial submission as a fully developed application. Inquiries not meeting the expedite guidelines will be guided to other grant mechanisms and to program contacts to discuss alternatives.
PAR-20-177 uses the R21 mechanism.The R21 activity code is intended to encourage new exploratory and developmental research projects that lack preliminary data. For example, such projects could assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Studies also may include the unique and innovative use of an existing methodology to explore a new scientific area. These studies may involve considerable success risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, reagents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
Applications for R21 awards should describe projects distinct from those supported through the traditional R01 activity code. For example, long-term projects, or projects designed to increase knowledge in a well-established scientific area, will not be considered for R21 awards. Applications submitted to this FOA should be exploratory and novel. These studies should break new ground or extend previous discoveries toward new directions or applications.
Applications will be accepted on a rolling basis, beginning on 04/30/2020. Applications will be handled on an expedited review and award basis to meet the goals of this program.
The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years.
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
*Full application in the "submit mode" and SFU Signature Sheet is due to ors@sfu.ca no later than 3 business days prior to the deadline. 8% of the direct costs is to be included as an overhead in the budget.
Reminder: Based on the revision of Postdoctoral fellow (PDF) policy (R50.03), please continue to include 14% of PDF benefit in all your proposal budgets.